GSK pledges transparency on drugs research data Sir Andrew said: "We need to take a different approach - one focused on partnership, collaboration and openness. By being more open with our clinical trial data, we also hope to help further scientific understanding. "Any form of openness and transparency in the pharmaceutical company is to be welcomed," he said. However, he said the scientific community would reserve judgement until it became clear how the process worked in practice. "It's nice to be optimistic but a drug company is not going to change its stripes overnight," he said. These are hard-headed business people. It's very encouraging but I think we'll wait to see what actually happens before passing any final judgment. In July this year, GSK reached a record $3bn settlement with the US government after pleading guilty to charges that it had provided misleading information on some drugs, including antidepressant Paxil and diabetes pill Avandia. GSK also announced on Thursday that it will make its library of compounds with potential activity against tuberculosis freely available to researchers. Investment in its Tres Cantos Lab, which allows independent researchers access to GSK facilities, will be doubled to £5m.